CURRICULUM VITAE. Andrea Marraffino, Ph.D.

Transcription

1 CURRICULUM VITAE CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (866) Fax (208) AFFILIATIONS: Florida Clinical Research Center, LLC 2300 Maitland Center Parkway Suite 230 Maitland, FL Lakeside Behavioral Healthcare 434 W. Kennedy Blvd. Orlando, FL EDUCATION: Andrea Marraffino, Ph.D. Florida Clinical Research Center, LLC 2300 Maitland Center Parkway Suite 230 Maitland, FL Health-Related Sciences, Ph.D. Specialization in Rehabilitation Counseling Virginia Commonwealth University, Richmond, VA 2006 Experimental Psychology, M.S. Behavioral Assessment and Analysis University of Texas at San Antonio, San Antonio, TX 2003 Psychology, B.A. University of Central Florida, Orlando, FL CERTIFICATION: Collaborative Institutional Training Initiative (CITI) 2004-Present Active US Dept of Defense Security Clearance-Secret Level 2011-Present Certified in Lab Specimen Collection and Processing

2 PROFESSIONAL EXPERIENCE: Investigator, Assistant Site Director, May Present Florida Clinical Research Center, LLC, Maitland, Florida Human-Systems Scientist, Functional and Project Manager, October 2011-May 2013 MESH Solutions, LLC A DSCI Company, Orlando, FL Senior Behavioral Sciences Research Associate, February 2010-October 2011 University of Central Florida, Institute for Simulation & Training, Orlando, FL Regulatory and IRB Specialist, October 2009-February 2010 M.D. Anderson Cancer Center, Clinical Trials Office, Orlando, FL Senior Clinical Research Associate, January 2006-October 2009 Louisiana State University, Clinical Trials Dept, Psychiatry, Baton Rouge, LA Graduate Research Assistant, August 2004-May 2006 University of Texas, Psychology Dept, NASA Research Lab, San Antonio, TX Graduate Research Assistant, August 2004-May 2006 University of Texas, Psychology Dept, DYAD Research Lab, San Antonio, TX Biofeedback Counselor, January 2001-August 2004 University of Central Florida, Campus Wellness Center, Orlando, FL CLINICAL EXPERIENCE: Addiction Alzheimer s Disease Anxiety Disorder Attention-Deficit/Hyperactivity Disorder Autism Spectrum Disorder Bipolar Disorder Major Depressive Disorder Post Traumatic Stress Disorder Schizophrenia or Schizoaffective Disorder SUB-INVESTIGATOR EXPERIENCE: ADHD Study to conduct psychometric tests on the electronic observer-reported (eobsro) Aggression Diary to evaluate whether the diary is a valid and reliable measure for assessing the benefit of XXX extended-release tablets for the treatment of Impulse Aggression Alzheimer s Disease A Validation Study of the Name-Face Memory Consolidation Test in Volunteers with Amnestic Mild Cognitive Impairment Updated 8/7/14 2

3 SUB-INVESTIGATOR EXPERIENCE (continued): Depression A Phase III Efficacy and Safety Study of XXX for the Adjunctive Treatment of Major Depressive Disorder A Phase III Multicenter Study of the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy Schizophrenia or Schizoaffective Disorder An Open-Label, Long-Term Safety and Tolerability Study of XXX in the Treatment of Subjects With Schizophrenia A Phase II, Randomized, Double-blind Study to Evaluate Efficacy, Safety, and Tolerability of XXX in Subjects with Schizophrenia with Alcohol Use Other Indications A Phase IIb, Randomized, Doub-Blind, Placebo-Controlled Study of XXX in Patients with Episodic Migraine SENIOR RESEARCH ASSOCIATE EXPERIENCE: ADHD A Randomized, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of an Investigational Medication in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems. Magnetic Resonance Imaging Studies of Two Approved ADHD Medications in ADHD Alzheimer s Disease Effect of an Investigational Medication a γ-secretase Inhibitor on the Progression of Alzheimer s Disease as Compared with Placebo. An open label, parallel group, multicenter study, evaluating the safety and imaging characteristics of an investigational radiopharmaceutical in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimer s disease (AD). Updated 8/7/14 3

4 SENIOR RESEARCH ASSOCIATE EXPERIENCE (continued): Anxiety, Panic Disorder and Social Phobia A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed- Dose Study Comparing the Efficacy and Safety of 3 Doses of an Investigational Medication in Acute Treatment of Adults with Generalized Anxiety Disorder. A Multi-centre, Double-blind, Randomized-Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of an Investigational Medication as Monotherapy in the Maintenance Treatment of Patients with Generalized Anxiety Disorder Following an Open- Label Stabilization Period. Open-Label Safety Study of an Investigational Medication in Patients with Anxiety Disorders. Sustained Efficacy Study of an Investigational Medication in Patients with Panic Disorder with or without Agoraphobia. A Sustained Efficacy Study of an Investigational Medication in Patients with Social Phobia. Flexible Dose Comparison of the Safety and Efficacy of an Investigational Medication, a Comparator Medication, and Placebo in the Treatment of Panic Disorder. Bipolar Disorder A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of an Investigational Medication in the Treatment of Bipolar I Depression. The Evaluation of an Investigational Medication as an Add-on Treatment for Bipolar Disorder in Children and Adolescents, 10 to 17 Years of Age. Four Week, Double-Blind, Placebo-Controlled Phase III Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Flexible Doses of an Oral Investigational Medication in Children and Adolescents with Bipolar I Disorder (Manic or Mixed). 26-Week, Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of an Oral Investigational Medication in Children and Adolescents with Bipolar I Disorder (Manic or Mixed). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of an Investigational Medication in the Maintenance Treatment of Patients with Bipolar Disorder. A Multicenter, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of an Investigational Medication Compared to Placebo in the Treatment of An Acute Manic or Mixed Episode in Patients Who Have Bipolar Disorder. Updated 8/7/14 4

5 SENIOR RESEARCH ASSOCIATE EXPERIENCE (continued): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of an Investigational Medication in the Treatment of Hospitalized Patients with Acute Mania. Depression A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of an Investigational Medication Versus Placebo in Acute Treatment of Adults with Major Depressive Disorder. A Multicenter, Randomized, 8-week Double-Blind, Acute Phase Followed by a 6-Month Continuation Phase (Open-Label or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of an Investigational Medication Versus Escitalopramin Postmenopausal Women with Major Depressive Disorder. A Multi-center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of an Investigational Medication in Combination with an Antidepressant in the Treatment of Patients with Major Depressive Disorder with Inadequate Response to an Antidepressant Treatment. An 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multicenter study of the efficacy, safety and tolerability of an investigational medication 25mg and 50mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension. A Multi-centre, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of an Investigational Medication Sustained Release as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period. A Randomized, Multicenter, 8-Week, Double-Blind, Placebo-Controlled Flexible Dose Study to Evaluate the Efficacy and Safety of an Investigational Medication in Children and Adolescents with Major Depressive Disorder. Placebo-Controlled Evaluation of the Safety and Efficacy of an Investigational Medication in the Prevention of Depression Relapse. Flexible Dose Comparison of the Safety and Efficacy of an Investigational Medication, a Comparator Medication and Placebo in the treatment of Major Depressive Disorder. Schizophrenia or Schizoaffective Disorder A 2-Year, Open-Label, Single-Arm Safety Study of a Flexibly Dosed Extended Release Investigational Medication (1.5-12mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia. Updated 8/7/14 5

6 SENIOR RESEARCH ASSOCIATE EXPERIENCE (continued): A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of an Investigational Medication 5,10, and 30 mg and Placebo on Top of an Established Treatment Regimen of Either Olanzapine, Risperidone/ Paliperidone, Quetiapine or Aripiprazole Monotherapy in the Treatment of Cognitive Impairment in Schizophrenia. Impact of Family Members Substance Abuse or Dependence on Schizophrenia A Multicenter, Randomized, Double-blind, Placebo-controlled, 16-Week Study of an Investigational Medication Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy. Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to Aripiprazole versus Continued Treatment with Olanzapine, Quetiapine, or Risperidone. A Multicenter, Randomized, Double-Blind Safety and Tolerability Study of Flexible Doses of an Investigational Medication in the Treatment of Patients with Acute Schizophrenia. The Comparison of Three Marketed Medications for Efficacy for Cognition in Schizophrenia. Other Indications Neurofunctional Correlates of Face Processing Deficits in Autism Spectrum Disorder using fmri. A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Commercially Available medication and a Commercially Available Medication in the Treatment of Cocaine Addiction. Early Intervention in Mild Cognitive Impairment (MCI) with Curcumin and Bioperine. A 16-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of an Investigational Medication in the Treatment of Pathological Gambling Disorder. A Double-Blind, Fixed Dose Comparison of an Investigational Medication and Placebo in Patients Suffering From Posttraumatic Stress Disorder (PTSD). Updated 8/7/14 6

7 PRESENTATIONS and PUBLICATIONS: INVITED PRESENTATIONS Marraffino, A. (2013, February). Stress Resilience Course. Presented at U.S. Ministry of Defense Advisors (MODAs) training program, 7 February 2013, Arlington, VA. Taylor, A. & Schatz, S. (2012). An Empirical Study Comparing Stress Induction Methods In the Laboratory. Presented at the 120 th American Psychological Association (APA) Convention s Prime Time poster session for Trends and Cross-Currents in Experimental and Comparative Psychology and Behavioral Neuroscience, 2-5 August 2012, Orlando, FL. *Winner of best poster presentation for the division Taylor, A. for Schatz, S., Wray, R., Folsom-Kovarik, J., & Nicholson, D. (2012). Adaptive Perceptual Training in a Virtual Environment. Presented at the 56 th Annual Meeting of the Human Factors and Ergonomics Society, October 2013, Boston, MA. PAPER PRESENTATIONS Bartlett, K., & Nolan, M., Marraffino, A. (2013). Intuitive Sensemaking: From Theory to Simulation-Based Training. Proceedings of the 2013 Human Computer Interaction International (HCII) Conference, 7 th International Conference on Augmented Cognition. Las Vegas, NV, July Marraffino, A., Schatz, S., Allen, C., & Tanaka, A. (2013). Macroergonomics, Simulation Systems, and the Nursing Shortage. Proceedings of the 2013 HFES International Symposium on Human Factors and Ergonomics in Healthcare. Baltimore, MD, March Taylor, A. H., Schatz, S., Carpenter, T., Carrizales, M. & Vogel-Walcutt, J. J. (2011). A review of military predeployment stress tolerance training. Paper presented at the 55 th Annual Meeting of the Human Factors and Ergonomics Society, Red Rock Hotel, Las Vegas, Nevada, 23 September Taylor, A. H. & Schatz, S. (2011). Measuring the effectiveness of stress prevention programs in military personnel. Paper presented at the Sixth Annual AugCog International Conference, Orlando, FL, 14 July JOURNAL ARTICLES Marraffino, A. & Schatz, S. (Under review). Assessing the Effects of Stress Resilience Training on Visual Discrimination Skills: Implications for Perceptual Resilience in U.S. Warfighters. Journal of Experimental Psychology: Human Perception and Performance. Smith, M., Taylor, A. & Kablinger, A. (2007). Comparing Demographics and Customer Satisfaction of Research Subjects to Psychiatry Clinic Patients. Journal of Clinical Research Best Practices, 3(11). Updated 8/7/14 7